Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.